This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Your search has found 494 articles in the database for the term 'Cognition (for those taking standard Alzheimer’s Disease medication)'

Click here to filter this large number of results.

The effect of an aloe polymannose multinutrient complex on cognitive and immune functioning in Alzheimer’s disease
...Participants tolerated the APMC supplement with few, temporary adverse reactions. Our results showed improvements in both clinical and physiological outcomes for a disease that otherwise has no standard ameliorative remedy.;...

A phase II trial of tideglusib in Alzheimer’s disease
...Background: The ARGO study was a phase II, double-blind, placebo controlled, four parallel arm trial of tideglusib in Alzheimer’s disease (AD). Objective: To prove the clinical efficacy of an...

Gait changes with anti-dementia drugs: a prospective, open-label study combining single and dual task assessments in patients with Alzheimer’s disease
...possible or probable Alzheimer’s disease before and after the use of acetylcholinesterase inhibitors (i.e., donepezil, galantamine, rivastigmine) or memantine, and among controls with possible or probable Alzheimer’s disease using no...

The mini-mental Parkinson’s (MMP) as a cognitive screening tool in people with Parkinson’s disease
...Background: Cognitive decline is common in Parkinson’s disease (PD) but may not be adequately identified by the mini-mental state examination (MMSE), which is better suited to Alzheimer’s disease. The...

Effects of galantamine in Alzheimer’s disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment
...galantamine 16 mg/day exhibited a mean (± standard error [SE]) improvement in 11-item cognitive subscale of the Alzheimer’s Disease Assessment Scale score of 1.8 (± 0.46) points at Week 6...

Cognitive-motor intervention in Alzheimer’s disease: Long-term results from the Maria Wolff trial
...mild cognitive impairment (MCI) and mild-to-moderate AD persons. Methods: Eighty-four non-institutionalized subjects with AD were randomized to receive either CMSI, administered by a single care provider, or standard support. Cognition,...

Long-term effects of galantamine on cognitive function in Alzheimer’s disease: a large-scale international retrospective study
...In Alzheimer’s disease (AD), it is important to consider long-term effects, not only in patients receiving treatment, but also in subjects in whom therapy has been discontinued. The present...

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease
...Background: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer’s disease.; Methods: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients...

Prevalence of anosognosia in Alzheimer’s disease
...Background and Objective: Anosognosia is a disorder that affects the clinical presentation of Alzheimer’s disease (AD), increasing in frequency with the evolution of AD. The objective was to determine...

Learning in Alzheimer’s disease is facilitated by social interaction
...Seminal work in Gary Van Hoesen’s laboratory at Iowa in the early 1980s established that the hallmark neuropathology of Alzheimer’s disease (AD; neurofibrillary tangles) had its first foothold in...

Search Again?

To make a new query of the database, please enter your search terms below:

�

Contact Us